For Emily Boller, it was a $5,000 hospital bill for a simple case of pink eye that took four years to pay off. For Mary Curley, it was the threatening collection letters from a lab that arrived more than 2½ years later, just as her husband lost his job and the family was fighting to save their home.
Lilly, Novo’s bet on heart disease starts to take shape, and 2024 could be a pivotal year for their GLP-1s
Eli Lilly and Novo Nordisk are steadily — and somewhat quietly — preparing to build comprehensive cardiovascular franchises helmed by their lucrative treatments for diabetes
December 20, 2023